LUM015 not checked

Lumicell, Inc.

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 1/2 trial completes
Trials
1 active
3 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Colorectal Cancer, Pancreatic Cancer, Esophageal Cancer, Gastric Cancer
Main trialPhase 1/2
“The overall goal of this feasibility study is to assess the initial safety and efficacy of LUM015 in ex vivo far-red imaging of colorectal, pancreatic, and esophageal cancers (adenocarcinoma) using the LUM Imaging System.”In the company’s words, NCT02584244 on ClinicalTrials.gov

Other drugs for Colorectal Cancer

All 392 drugs for Colorectal Cancer

Coming up1

Changes2

Last 90 days

Trials3

TrialPhaseCompletesWhat it tests
Phase 1/2Active, not recruiting Feb 2027 Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
Phase 2Terminated 30 Nov 2023 Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients
Phase 1/2Completed Sep 2017 Feasibility Study of Intraoperative Imaging in Breast Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow LUM015

Following is part of Solo: you see every change to LUM015 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in